Inventor · disambiguated record
John Gatfield
Also filed as: GATFIELD JOHN
13 granted patents·7 pending applications·27 citations·filing 2007–2025
87Inventor score
Files withIDORSIA PHARMACEUTICALS LTD14AISSAOUI HAMED2BOSS CHRISTOPH2ACTELION PHARMACEEUTICALS LTD1ACTELION PHARMACEUTICALS LTD1
Top patents by PatentIndex Score
20 records- 0185US10065929B2Pyrazole compounds and their use as T-type calcium channel blockersIDORSIA PHARMACEUTICALS LTD·Filed 2017·Granted Sep 4, 2018·5 cites·30 claims
- 0284US9932314B2Pyrazole compounds and their use as T-type calcium channel blockersIDORSIA PHARMACEUTICALS LTD·Filed 2015·Granted Apr 3, 2018·5 cites·28 claims
- 0383US9211279B2Proline sulfonamide derivatives as orexin receptor antagonistsACTELION PHARMACEUTICALS LTD·Filed 2015·Granted Dec 15, 2015·3 cites·30 claims
- 0482US10246426B2Triazole compounds as T-type calcium channel blockersIDORSIA PHARMACEUTICALS LTD·Filed 2015·Granted Apr 2, 2019·5 cites·13 claims
- 0581US8895606B2Proline sulfonamide derivatives as orexin receptor antagonistsBOSS CHRISTOPH·Filed 2011·Granted Nov 25, 2014·5 cites·9 claims
- 0680US9000029B2Proline sulfonamide derivatives as orexin receptor antagonistsBOSS CHRISTOPH·Filed 2014·Granted Apr 7, 2015·4 cites·13 claims
- 0772US2025257056A1Alpha-d-galactopyranoside derivativesIDORSIA PHARMACEUTICALS LTD·Filed 2025·Application pending·0 cites
- 0865US2025268979A1Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiatorsIDORSIA PHARMACEUTICALS LTD·Filed 2023·Application pending·0 cites
- 0961US12319672B2Alpha-D-galactopyranoside derivativesIDORSIA PHARMACEUTICALS LTD·Filed 2020·Granted Jun 3, 2025·0 cites·23 claims
- 1057US12304902B2Hydroxyheterocycloalkane-carbamoyl derivativesIDORSIA PHARMACEUTICALS LTD·Filed 2022·Granted May 20, 2025·0 cites·13 claims
- 1157US12291520B2Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivativesIDORSIA PHARMACEUTICALS LTD·Filed 2021·Granted May 6, 2025·0 cites·20 claims
- 1256US12312362B2Spiro derivatives of Alpha-D-galactopyranosidesIDORSIA PHARMACEUTICALS LTD·Filed 2021·Granted May 27, 2025·0 cites·18 claims
- 1356US2024109930A1Triazolyl-methyl substituted alpha-d-galactopyranoside derivativesIDORSIA PHARMACEUTICALS LTD·Filed 2022·Application pending·0 cites
- 1452US2011086889A1Tetrazole compounds as orexin receptor antagonistsAISSAOUI HAMED·Filed 2009·Application pending·0 cites
- 1552US2024208992A1Macrocycles as cftr modulatorsIDORSIA PHARMACEUTICALS LTD·Filed 2021·Application pending·0 cites
- 1650US12410208B2(2-acetamidyl)thio-beta-D-galactopyranoside derivativesIDORSIA PHARMACEUTICALS LTD·Filed 2020·Granted Sep 9, 2025·0 cites·15 claims
- 1750US12404295B2(Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivativesIDORSIA PHARMACEUTICALS LTD·Filed 2020·Granted Sep 2, 2025·0 cites·15 claims
- 1849US12291519B22-hydroxycycloalkane-1-carbamoylIDORSIA PHARMACEUTICALS LTD·Filed 2020·Granted May 6, 2025·0 cites·16 claims
- 1945US2010022568A1Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosisACTELION PHARMACEEUTICALS LTD·Filed 2007·Application pending·0 cites
- 2036US2012088759A1Thiazolidin-4-one and [1,3]-thiazinan-4-one compounds as orexin receptor antagonistsAISSAOUI HAMED·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when John Gatfield files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →